Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Niraparib · Zejula

Small molecule · Inhibitor of PARP-1 and PARP-2 · developed by Glaxosmithkline

Approved FDA, Mar 2017
1 Registered trials

What is Niraparib?

Niraparib is a PARP-1 and PARP-2 inhibitor that blocks DNA repair enzymes, leading to DNA damage, apoptosis, and cell death in tumor cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zejula
Drug type
Small molecule
Targets
PARP-1, PARP-2
Mechanism
Inhibitor of PARP-1 and PARP-2
Pathways
DNA repair, apoptosis
Therapy area
Oncology
Developer
Glaxosmithkline
In trials of
PBYI
FDA status
Approved as Zejula (March 27, 2017), NDA208447 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04502602 Phase 1 Advanced Solid Tumor Active not recruiting PBYI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorOvarian Cancer

Other drugs acting on PARP1 / PARP2

Olaparib FDA approved 2X-121 Phase 2 EIK1004 Investigational IMP1734 Investigational Senaparib Investigational Veliparib Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.